| Literature DB >> 33321102 |
Guobin Xie1, Yuqi Zhou2, Xuhuang Tu1, Xiaohong Ye1, Lin Xu1, Zhijian Xiao1, Qiqiang Wang1, Xin Wang1, Mingxuan Du1, Ziwen Chen2, Xiaoqin Chi3, Xiaoli Zhang1, Ji Xia1, Xiaowei Zhang1, Yunxia Zhou1, Zongxi Li1, Chengrong Xie3, Luoyan Sheng1, Zhiping Zeng1, Hu Zhou1, Zhenyu Yin3, Ying Su2, Yang Xu1, Xiao-Kun Zhang4.
Abstract
Retinoid X receptor alpha (RXRα), a nuclear receptor of transcription factor, controls various physiological and pathological pathways including cellular growth, proliferation, differentiation, and apoptosis. Here, we report that RXRα is phosphorylated at its N-terminal A/B domain by cyclin-dependent kinase 1 (Cdk1) at the onset of mitosis, triggering its translocation to the centrosome, where phosphorylated-RXRα (p-RXRα) interacts with polo-like kinase 1 (PLK1) through its N-terminal A/B domain by a unique mechanism. The interaction promotes PLK1 activation, centrosome maturation, and mitotic progression. Levels of p-RXRα are abnormally elevated in cancer cell lines, during carcinogenesis in animals, and in clinical tumor tissues. An RXRα ligand XS060, which specifically inhibits p-RXRα/PLK1 interaction but not RXRα heterodimerization, promotes mitotic arrest and catastrophe in a tumor-specific manner. These findings unravel a transcription-independent action of RXRα at the centrosome during mitosis and identify p-RXRα as a tumor-specific vulnerability for developing mitotic drugs with improved therapeutic index.Entities:
Keywords: Cdk1; PLK1; RXRα; RXRα ligand; RXRα phosphorylation; catastrophe; centrosome; mitosis; nuclear receptor; tumor vulnerability
Year: 2020 PMID: 33321102 DOI: 10.1016/j.devcel.2020.11.012
Source DB: PubMed Journal: Dev Cell ISSN: 1534-5807 Impact factor: 12.270